Conference Coverage
Advertisement
Dr. Peshin gives her thoughts on the future of GI oncology and the research that she found most interesting at ASCO GI 2025.
Dr. Strosberg focuses on how previous exposure to alkylating agents can influence tumor biology or immune response.
Mara B. Antonoff, MD, FACS, shares key considerations and developments in surgery for stage IV lung cancer.
The study showed that favezelimab/pembrolizumab did not demonstrate a survival benefit over SOC.
Dr. Pasche discusses the trial that led to the TheraBionic P1 device's regulatory approval by the FDA.
However, the study findings presented at STS 2025 suggest that segmentectomy may be a “viable alternative” to lobectomy.
Dr. Pant shared updates on a phase 1b dose escalation trial of gemcitabine, nab-paclitaxel, and lixumistat.
Dr. Pant offered insights on the key findings of zanidatamab's efficacy and safety in HER2-positive BTC.
Dr. Weinberg provided his perspective on the CheckMate 9DW expanded analyses, as well as multiple studies in CRC.
Dr. Shirakawa highlighted the results of the NAPOLEON-2 trial, including how RWD compare to clinical trial findings.
Dr. Dotan shared the effects of baseline geriatric and QOL assessments on outcomes for older patients with pancreatic cancer.
Dr. Abdelrahim details the impact of UGT1A1*28 polymorphism on tolerability in patients with mPDAC in the NAPOLI 3 study.
Previous data pointed to the benefit of adjuvant immunotherapy for patients with HCC through the use of CIK cells.
Previously presented results of the trial showed favorable PFS rates in the m-FOLFOXIRI and cetuximab arm.
Dr. Lieu details practice-changing studies from ASCO GI 2025, including CheckMate-9DW, CheckMate 8HW, and BREAKWATER.
The combination of EVE/LAN can significantly prolong PFS in patients with well-differentiated grade 1/2 GEP-NETs.
ASPEN-06 analyzed the CD47 myeloid checkpoint inhibitor ALX148 in patients with HER2-overexpressing gastric cancer.
In EMERALD-1, investigators analyzed the combination of durvalumab plus bevacizumab and TACE versus placebo with TACE.
Additional analyses from the CheckMate 9DW study shed further light on the clinical efficacy and safety of ipi/nivo for uHCC.
Results of NIR-B trial sheds light on the clinical utility of niraparib in patients with BRCA-mutated GI cancers.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.